Antibodies persist six months after second Moderna COVID-19 jab

7 April 2021

Antibody activity remained high in all age groups beyond six months after the second dose of Moderna’s (Nasdaq: MRNA) COVID-19 vaccine, according to research published in the New England Journal of Medicine.

Phase I results show that antibodies that were elicited by COVID-19 Vaccine Moderna persisted through six months after the second dose, as detected by three distinct serologic assays.

Ongoing studies are monitoring immune responses beyond six months as well as determining the effect of a booster dose to extend the duration and breadth of activity against emerging viral variants.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK